Insmed Inc’s recently made public that its Officer Smith Michael Alexander acquired Company’s shares for reported $72114.0 on Jul 11 ’25. In the deal valued at $96.41 per share,748 shares were bought.
Then, Bonstein Sara sold 57,764 shares, generating $5,537,460 in total proceeds. Upon selling the shares at $95.86, the Chief Financial Officer now owns 84,017 shares.
Before that, Bonstein Sara bought 57,764 shares. Insmed Inc shares valued at $5,535,591 were divested by the Officer at a price of $95.83 per share.
Jefferies initiated its Insmed Inc [INSM] rating to a Buy in a research note published on May 13, 2025; the price target was $105. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Truist began covering INSM with “Buy” recommendation on April 23, 2024. Wolfe Research started covering the stock on February 15, 2024. It rated INSM as “an Outperform”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock jump 1.57% to $98.18. Over the last five days, the stock has gained 0.39%. Insmed Inc shares have risen nearly 39.72% since the year began. Nevertheless, the stocks have risen 42.21% over the past one year. While a 52-week high of $106.83 was reached on 06/25/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 96.30, which if violated will result in even more drops to 94.41. On the upside, there is a resistance level at 99.73. A further resistance level may holdings at 101.27.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-06-13, dropping by -4.82 million shares to a total of 11.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 16.47 million shares. There was a decline of -41.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $55 price target.
